Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (Review)

International Journal of Oncology

Volumn 13, Issue 5, 1998, Pages 893-906

  Reuning, Ute ^a   Magdolen, Viktor ^a   Wilhelm, Olaf ^a   Fischer, Kerstin ^a   Lutz, Verena ^a   Graeff, Henner ^a   Schmitt, Manfred ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Invasion; Metastasis; Plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; SERINE PROTEINASE; UROKINASE;

CANCER INVASION; CELL ADHESION; CHEMOTAXIS; HUMAN; METASTASIS; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT PLANNING; TUMOR GROWTH;

EID: 0031733174     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.5.893     Document Type: Review

References (207)

1. Danø K, Andrcascn PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS and Skrivcr L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266, 1985.
2. Markus G: The relevance of plasminogen activators to neoplastic growth. Adv Cancer Res 44: 158-172, 1988.
3. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F and Graeff H: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: proenostic relevance and target for therapy. Thromb Haemost 78: 285-296, 1997.
4. Mignatti P and Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195, 1993.
5. Quigley JP, Gold LI, Schwimmer R and Sullivan LM: Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells. Proc Natl Acad Sci USA 84: 2776-2780, 1987.
6. Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S and Mignatti P: Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16: 2319-2332, 1997.
7. Vassalli JD, Baccino D and Belin D: A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86-92, 1985.
8. Ellis V, Wun TC, Behrendt N, Rønne E and Danø K: Inhibition of receptor-bound urokinase by plasminogen activator inhibitors. J Biol Chem 265: 9904-9908, 1990.
9. Sier CFM, Vloedgracen HJM, Ganesh S, Griffioen PHA, Quax JH, Verheijen G, Dooijewaard G, Welvaart K, van de Velde CJH and Lamers CBHW: Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 107: 1449-1456, 1994.
10. Cubellis MV, Wun TC and Blasi F: Receptor-mediated internalization and decradation for urokinase is caused by its specific inhibitor PAI-1. EMBO J 9: 1079-1085, 1990.
11. Limongi P, Resnati M, Henandez-Marrero L, Cremona O, Blasi F and Fazioli F: Biosynthesis and apical localization of the urokinase receptor in polarized MDCK epithelial cells. FEBS Lett 369: 207-211, 1995.
12. Estreicher A, Mühlhauser J, Carpentier JL, Orci L and Vassalli JD: The receptor for urokinase-type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 111: 783-792, 1990.
13. Fidler IJ, Gersten DM and Hart IR: The biology of cancer invasion and metastasis. Adv Cancer Res 28: 149-250, 1978.
14. Dvorak HF: Thrombosis and cancer. Hum Pathol 18: 275-284, 1987.
15. Rickles FR and Edwards RL: Activation of blood coagulation in cancer. Blood 62: 14-31, 1983.
16. Gordon SG: Cancer procoagulant. Methods Enzymol 244: 568-583, 1994.
17. Bastida E, Ordinas A, Escolar G and Jamieson JA: Tissue factor on microvesicles shed from U87 MG human glioblastoma cells induces coagulation, platelet asgregation, and thrombogenesis. Blood 64: 177-184, 1984.
18. Donati MB: Cancer and thrombosis. Thromb Haemost 74: 278-281, 1995.
19. Dvorak HF, van Devater L, Bitzger AM, Dvorak AM, Anderson D, Harvey VS, Bach R, Davis GL, Dewolf W and Carvalho CA: Procoagulant activity associated with plasma membrane vesicles shed by cultures tumor cells. Cancer Res 43: 4334-4342, 1983.
20. Walz DA and Fenton JW: The role of thrombin in tumor metastasis. Invasion Metastasis 14: 303-308, 1995.
21. Besser D, Verde P, Nagamine Y and Blasi F: Signal transduction and the u-PA/u-PAR system. Fibrinolysis 10: 215-237, 1996.
22. Goretzki L, Schmitt M, Mann K, Calvete J, Chucholowski N, Kramer M, Günzler WA, Jänieke F and Graeff H: Effective activation of the proenzyme form of urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett 297: 112-118, 1992.
23. Ichinose A, Fijikama K and Suyama T: The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 261: 3486-3489, 1986.
24. Kobayashi H, Schmitt M, Gorctzki L, Cucholowski N, Calvete J, Kramer M, Günzler AW, Jänieke F and Graeff H: Cathepsin B efficiently activates the soluble and the tumor cell receptor bound form of the proenzyme urokinase-type plasminogen activator (Pro-u-PA). J Biol Chem 266: 5147-5152, 1991.
25. Wolf B, Vasudevan J, Henkin J and Gonias S: Nerve growth factor-γ activates soluble and receptor-bound single chain urokinase-type plasminogen activator. J Biol Chem 268: 16327-16331, 1993.
26. Andreasen PA, Nielsen LS, Kristensen P, Grøndahl-Hansen J, Skriver L and Danø K: Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem 261: 7644-7651, 1986.
27. Ploug M, Behrendt N, Lober D and Danø K: Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin Thromb Hemost 17: 183-193, 1991.
28. Chucholowski N, Schmitt M, Rettenberger P, Schüren E, Moniwa N, Goretzki L, Wilhelm O, Weidle U, Jänicke F and Graeff H: Flow cytofluorometric analysis of the urokinase receptor (uPA-R) on tumor cells by fluorescent uPA-ligand or monoclonal antibody #3936. Fibrinolysis 6: 95-102, 1992.
29. Andreasen PA, Sottrup-Jensen L, Kloller L, Nykjaer A, Moestrup SK, Munch-Petersen C and Gliemann J: Receptor-mediated endocytosis of plasminogen activators and activator/ inhibitor complexes. FEBS Lett 338: 239-245, 1994.
30. Nykjaer A, Petersen CM, Moller B, Jensen PH, Moestrup SK, Holtet TL, Etzerod M, Thorgersen HC, Munch M, Andreasen PA and Gliemann J: Purified alpha-2 macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 267: 14543-14546, 1992.
31. Magdolen V, Rettenberger P, Koppitz M, Goretzki L, Kessler H, Weidle UH, König B, Gracff H, Schmitt M and Wilhelm O: Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur J Biochem 237: 743-751, 1996.
32. Goodson RJ, Doyle MV, Kaufman SE and Rosenberg S: High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci USA 91: 7129-7133, 1994.
33. Nykjaer A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J and Blasi F: Recycling of the urokinase receptor upon internalization of the uPA: serpin complexes. EMBO J 16: 2610-2620, 1997.
34. Liu G, Shuman MA and Cohen RL: Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 60: 501-506, 1995.
35. Keski-Oja J, Koli K, Lohi J and Laiho M: Growth factors in the regulation of plasminogen plasmin system in tumor cells. Semin Thromb Hemost. 17: 231-239, 1991.
36. McGuire WL, Tandon AK, Allred DC, Chamness GC and Clark GM: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82: 1006-1015, 1990.
37. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Lijnen HR: Tissue type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 48: 1348-1349, 1988
38. Jänicke F, Schmitt M, Ulm K, Gössner W and Graeff H: Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 8670: 1049, 1989.
39. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N and Fennelly JJ: Urokinase plasminogen activator and prognosis in breast cancer. Lancet 335: 108, 1990.
40. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JN and Andreasen PA: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829, 1990
41. Duffy MJ: Plasminogen activators and cancer. Blood Coagul Fibrinolysis 1: 681-687, 1990.
42. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W and Graeff H: Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78, 1990.
43. Schmitt M, Jänicke F and Graeff H: Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul Fibrinolysis 1: 695-702, 1990.
44. Foucre D, Bouchet C, Hacene K, Pourreau-Schneider N, Gentile A, Martin PM, Desplaces A and Oglobinc J: Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer 64: 926-932, 1991.
45. Jänicke F, Schmitt M and Graeff H: Clinical relevance of the urokinase-type and the tissue-type plasminogen activators and of their inhibitor PAI-1 in breast cancer. Semin Thromb Hemost 17: 303-312, 1991.
46. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Jänicke F and Klijn JGM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992.
47. Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero-Pous M, Deytieux S, Le Doussal V, Tubiana-Hulin M and Brunet M: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266-1272, 1992.
48. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K and Blichert-Toft M: High levels of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993.
49. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Holler H and Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong, independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208, 1993.
50. Rosenquist C, Thorpe SM, Danø K and Grøndahl-Hansen J: Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res Treat 28: 223-229, 1993.
51. Yamashita J, Ogawa M, Yamashita S, Nakashima Y, Saishoji T, Nomura K, Inada K and Kawano I: Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer. Br J Cancer 68: 524-529, 1993.
52. Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A and Oglobine J: Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405, 1994.
53. Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ and Andreasen PA: Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 74: 2276-2280, 1994.
54. Foekens JA, Schmitt M, Peters HA, Look MP, van Putten WLJ, Kramer MD, Jänicke F and Klijn GM: Association of PAI-1 with metastasis-free survival in breast cancer: comparison with ER, PgR, PS2, cathepsin D and uPA. In: Prospects in Diagnosis and Treatment of Cancer. International Congress Series, Excerpta Medica 1050. Schmitt M, Graeff H and Kindermann G (eds.) Elsevier, Amsterdam, pp 197-205, 1994.
55. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Jänicke F and Klijn JGM: Plasminogen activator inhibitor-1 and breast cancer metastasis. J Clin Oncol 12: 1648-1658, 1994.
56. Jänicke F, Thomssen C, Pache L, Schmitt M and Graeff H: Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In: Prospects in Diagnosis and Treatment of Cancer. International Congress Series, Excerpta Medica 1050. Schmitt M, Graeff H and Kindermann G (eds.) Elsevier, Amsterdam, pp207-218, 1994.
57. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A and Graeff H: Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor type T. Cancer Res 54: 2527-2530, 1994.
58. Romain S, Chinot O, Klijn JG, van Putten WL, Guirou O, Look M, Martin PM and Foekens JA: Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients. Br J Cancer 70: 304-308, 1994.
59. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ and Duffy MJ: Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61: 597-600, 1995.
60. Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WL, Look MP, Klijn JG and Krämer MD: Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55: 1423-1427, 1995.
61. Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H and Klijn JG: Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751-756, 1995.
62. Foekens JA, Klijn JGM, Natoli C, van Putten WLJ, Di Stefano P, Look MP, Portengen H and Jacobelli S: Expression of tumor-associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen. Int J Cancer 64: 130-134, 1995.
63. Grøndahl-Hansen J, Peters HA, van Putten WLJ, Look MP, Pappot H, Rønne E, Danø K, Klijn JGM, Br̈nner N and Foekens JA: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1: 1079-1087, 1995.
64. Yamashita J, Ogawa M and Sakai K: Prognostic significance of three novel biological factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery 117: 601-608, 1995.
65. Duffy MJ, Duggan C, Maguire T, Mulcahy K, Elvin P, McDermott E, Fennelly JJ and O'Higgins N: Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enzyme Protein 49: 85-93, 1996.
66. Fernö M, Bendahl PO, Borg A, Brundell J, Hirschberg L, Olsson H and Killander D: Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 32A: 793-801, 1996.
67. Fersis N, Kaufmann M, Kramer MD, Wallwiener D and Bastert G: Prognostische Bedeutung des Plasminogenaktivator inhibitor-1 (PAI-1) beim primären Mammakarzinom. Geburtshilfe Frauenheilkd 56: 28-34, 1996.
68. Ishikawa K, Noguchi S, Tanaka K, Fukuda A and Hirohata T: Second primary neoplasms in thyroid cancer patients. Jpn J Cancer Res 87: 232-239, 1996.
69. Mayerhofer K, Stolzlechner J, Yildiz S, Haider K, Heinzl H, Jakesz R, Pecherstorfer M, Rosen H, Sevelda P, Zeillinger R and Speiser P: Plasminogenaktivator inhibitor 1 und Prognose beim Mammakarzinom. Geburtshilfe Frauenheilkd 56: 23-27, 1996.
70. Duggan C, Kennedy S, Kramer MD, Barnes C, Elvin P, McDermott E, O'Higgins N and Duffy MJ: Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer 76: 622-627, 1997.
71. Grøndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK and Brünner N: Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 43: 153-163, 1997.
72. Kim SJ, Shiba E, Taguchi T, Watanabe T, Tanji Y, Kimoto Y, Izukura M and Takai SI: Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer. Anticancer Res 17: 1373-1378, 1997.
73. Ruppert C, Ehrenforth S, Scharrer I and Halberstadt E: Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer. Cancer Detect Prev 21: 452-459, 1997.
74. Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, Jänicke F and Graeff H: Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1, and steroid hormone receptor status in primary breast cancer. Br J Cancer 76: 306-331, 1997.
75. Shiba E, Kim SJ, Taguchi T, Izukura M, Kobayashi T, Furukawa J, Yayoi E, Shin E, Takatsuka Y, Koyama H and Takai S: A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissue. J Cancer Res Clin Oncol 123: 555-559, 1997.
76. Umeda T, Eguchi Y, Okino K, Kodama M and Hattori T: Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J Pathol 183: 388-397, 1997.
77. Bouchet C, Spyratos F, Hacene K, Durcos L, Becette V and Oglobine J: Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods. Br J Cancer 77: 1495-1501, 1998.
78. Duffy MJ, Duggan C, Mulcahy HE, McDermott EW and O'Higgins NJ: Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease. Clin Chem 44: 1177-1183, 1998.
79. Harbeck N, Dettmar P, Thomssen C, Henselmann B, Kuhn W, Ulm K, Jänicke F, Höfler H, Graeff H and Schmitt M: Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Res 18: 2187-2197, 1998.
80. Kim SJ, Shiba E, Kobayashi T, Yayoi E, Furukawa J, Takatsuka Y, Shin E, Koyama H, Inaji H and Takai S: Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 4: 177-182, 1998.
81. Knoop A, Andreasen PA, Andersen JA, Hansen S, Laenkholm AV, Simonsen AC, Andersen J and Overgaard J: Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 77: 932-940, 1998.
82. Kute TE, Grøndahl-Hansen J, Shao SM, Long R, Russell G and Brünner N: Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node-negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 47: 9-16, 1998.
83. Peyrat JP, Vanlemmens L, Fournier J, Huet G, Revillon F and Bonneterre J: Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancer. Clin Cancer Res 4: 189-196, 1998.
84. Thomssen C, Oppelt P, Jänicke F, Ulm K, Harbeck N, Höfler H, Kuhn W, Graeff H and Schmitt M: Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Anticancer Res 18: 2173-2180, 1998.
85. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F and Graeff H: Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55: 401-409, 1994.
86. Kobayashi H, Fujishiro S and Terao T: Impact of urokinase-type plasminogen activator and its inhibitor type-1 on prognosis in cervical cancer of the uterus. Cancer Res 54: 6539-6548, 1994.
87. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y and Sumiyoshi A: The content of urokinase-type plasminogen antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 50: 871-873, 1992.
88. Hasui Y, Nishi S, Kitada S and Osada Y: Urokinase-type plasminogen activator antigen as a prognostic factor in bladder cancer. Nippon Hinyokika Gakkai Zasshi 84: 1624-1628, 1993.
89. Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y and Sumiyoshi A: The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer. J Urol 151: 16-19, 1994.
90. Hasui Y, Marutsuka K, Asada Y and Osada Y: Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology 47: 34-37, 1996.
91. Nakanishi K, Kawai T, Torikata C, Aurues T and Ikeda T: Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma. Cancer 82: 724-732, 1998.
92. Hofmann R, Lehmer A, Hartung R, Robrecht C, Buresch M and Grothe F: Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J Urol 155: 858-862, 1996.
93. Hofmann R, Lehmer A, Buresch M, Hartung R and Ulm K: Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 78: 487-492, 1996.
94. Itaya T, Motai H, Suzuki K and Baba S: Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinoma. Nippon Jibiinkoka Gakkai Kaiho 98: 197-202, 1995.
95. Bindal AK, Hammoud M, Shi WM, Wu SZ, Sawaya R and Rao JS: Prognostic significance of proteolytic enzymes in human brain tumors. J Neurooncol 22: 101-110, 1994.
96. Hsu DW, Efird JT and Hedley-Whyte ET: Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 147: 114-123, 1995.
97. Pedersen H, Brünner N, Francis D, Osterlind K, Rønne E, Hansen HH, Danø K and Grøndahl-Hansen J: Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and larse cell lung cancer tissue. Cancer Res 54: 4671-4675, 1994.
98. Pedersen H, Grøndahl-Hansen J, Francis D, Osterlind K, Hansen HH, Danø K and Brünner N: Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54: 120-123, 1994.
99. Pappot H and Brünncr N: The plasminogen activation system and its role in lung cancer. A review. Lung Cancer 12: 1-12, 1995.
100. Pavey SJ, Marsh NA, Ray MJ, Butler D, Dare AJ and Hawson GA: Changes in plasminogen activator inhibitor-1 levels in non-small lung cancer. Boll Soc Ital Biol Sper 72: 331-340, 1996.
101. Pappot H, Skov BG, Pyke C and Grøndahl-Hansen J: Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry. Lung Cancer 17: 197-209, 1997.
102. Choong PFM, Ferno M, Akerman M, Willen H, Langstrom E, Gustafson P, Alvegard T and Rydholm A: Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int J Cancer 69: 268-272, 1996.
103. Nekarda H, Siewert JR, Schmitt M and Ulm K: Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet 343: 117, 1994.
104. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U and Siewert JR: Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54: 2900-2907, 1994.
105. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW and Schildberg FW: Individual development and uPA-receptor expression of disseminated tumor cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1: 1035-1039, 1995.
106. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U and Schildberg FW: Tumor associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase type plasminogen activator system. J Clin Oncol 13: 2084-2093, 1995.
107. Herszenyi L, Plebani M, Cardin R, Carraro P, De Paoli MD, Roveroni G, Naccarato R and Farinati F: The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in castric cancer. Acta Physiol Hung 83: 213-221, 1995.
108. Plebani M, Herszenyi L, Cardin R, Roveroni G, Carraro P, Paoli MD, Rugge M, Grigioni WF, Nitti D and Naccarato R: Cysteine and serine proteases in gastric cancer. Cancer 76: 367-375, 1995.
109. Yonemura Y, Nojima N, Kaji M, Fujimura T, Itoh H, Ninomiya I, Miyazaki I, Endo Y and Sasaki T: E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer 76: 941-953, 1995.
110. Ganesh S, Sier CFM, Heerding MM, van Krieken JHJM, Griffioen G, Welvaart K, van de Velde CJH, Verheijen JH, Lamers CBHW and Verspaget HW: Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer 77: 1035-1043, 1996.
111. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U and Schildberg FW: The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer. Eur J Surg Oncol 22: 74-77, 1996.
112. Herszenyi L, Farinati F, Plebani M, Carraro P, Roveroni G, De Paoli MD, Cardin R, Naccarato R and Tulassay Z: Prognostic role of cysteine and serine proteases in gastric cancer. Orv Hetil 137: 1637-1641, 1996.
113. Ito H, Yonemura Y, Fujita H, Tsuchihara K, Kawamura T, Nojima N, Fujimura T, Nose H, Endo Y and Sasaki T: Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Virchows Arch (A) 427: 487-496, 1996.
114. Maeda K, Chung YS, Sawada T, Ogawa Y, Onoda N, Nakata B, Kato Y and Sowa M: Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma. Int J Oncol 8: 499-503, 1996.
115. Allgayer H, Babic R, Gruetzner KU, Beyer BC, Tarabichi A, Wilhelm-Schildberg F and Heiss MM: An immunohistochemical assessment of cathepsin D in gastric cancer: its impact on clinical prognosis. Cancer 80: 179-187, 1997.
116. Allgayer H, Heiss MM, Riesenberg R, Gruetzner KU, Tarabichi A, Babic R and Schildberg FW: Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res 57: 1394-1399, 1997.
117. Allgayer H, Heiss MM and Schildberg FW: Prognostic factors in gastric cancer. Br J Surg 84: 1651-1664, 1997.
118. Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW and Schildbcrg FW: Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg 226: 736-745, 1997.
119. Cho JY, Chung HC, Noh SH, Roh JK, Min JS and Kim BS: High level of urokinase-type plasminogen activator is a new prognostic marker in patients with castric carcinoma. Cancer 79: 878-883, 1997.
120. Plebani M, Herszeny L, Carraro P, De Paoli M, Roveroni G, Cardin R, Tulassay Z, Naccarato R and Farinati F: Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clin Exp Metastasis 15: 418-425, 1997.
121. Taniguchi K, Yonemura Y, Nojima N, Hirono Y, Fujimura T, Miwa K, Endo Y, Yamamoto H and Watanabe H: The relation between the growth patterns of gastric carcinomas and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82: 2112-2122, 1998.
122. Allgayer H, Babic R, Gruetzner KU, Beyer BC, Tarabichi A, Schildberg FW and Heiss MM: Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis 16: 62-73, 1998.
123. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB and Verspaget HW: Urokinase receptor and colorectal cancer survival. Lancet 344: 401-402, 1994.
124. Ganesh S, Sier CF, Griffioen G, Vloedgraven HJ, De Boer A, Welvaart K, van de Velde CJ, van Krieken JH, Verheijen JH, Lamers CB and Verspaget HW: Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54: 4065-4071, 1994.
125. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghuc DP and Sheahan K: Urokinase-type plasminogen activator and outcome in Dukes B colorectal cancer. Lancet 344: 583-584, 1994.
126. Buo L, Meling GI, Karlsrud TS, Johansen HAT and Aasen AO: Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aegressiveness. Hum Pathol 26: 1133-1138, 1995.
127. Sato T, Nishimura G, Yonemura Y, Nojima N, Ninomiya I, Fujimura T, Sugiyama K, Miwa K, Miyazaki I and Nonomura A: Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology 52: 347-352, 1995.
128. Verspaget HW, Sier CF, Ganesh S, Griffioen G and Lamers CB: Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur J Cancer 31A: 1105-1109, 1995.
129. Ganesh S, Sier CF, Heerding MM, van Krieken JH, Griffioen G, Welvaart K, van de Velde CJ, Verheijen JH, Lamers CB and Verspaget HW: Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer 75: 1793-1801, 1997.
130. Tatsuta S, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G and Shimamoto F: Combined expression of urokinase-type plasminogen activator and proliferating cell nuclear antigen at the deepest invasive portion correlates with colorectal cancer prognosis - clinical studies. Int J Oncol 10: 125-129, 1997.
131. Berney CR, Yang J, Fisher RJ, Russell PJ and Crowe PJ: Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. Oncol Res 10: 47-54, 1998.
132. Kim SJ, Shiba E, Tsukamoto F, Izukura M, Taguchi T, Yoneda K, Tanji Y, Kimoto Y and Takai SI: The expression of urokinase type plasminogen activator is a novel prognostic factor in Dukes B and C colorectal cancer. Oncol Rep 5: 431-435, 1998.
133. Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, Riesle E, Korc M and Buchler MW: Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 75: 388-395, 1997.
134. Nekarda H, Schlegel P, Schmitt M, Stark M, Mueller JD, Fink U and Siewert JR: Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res 4: 1755-1763, 1998.
135. De Petro G, Tavian D, Copcta A, Portolani N, Giulini SM and Barlati S: Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res 58: 2234-2239, 1998.
136. McGuire WL and Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326: 1756-1761, 1991.
137. Duffy MJ: Protcases as prognostic markers. Clin Cancer Res 2: 613-618, 1996.
138. Duffy M, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Lijnen HJ: Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer 62: 531-533, 1988.
139. Deng G, Waltz DA, Navaneetha R, Drummond RJ, Rosenberg S and Chapman HA: Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269: 32380-32388, 1994.
140. Deng G, Curriden SA, Wang S, Rosenberg S and Loskutoff D: Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release. J Cell Biol 134: 1563-1571, 1996.
141. Kanse S, Kost C, Wilhelm O, Andreasen PA and Preissner KT: The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 224: 344-353, 1996.
142. Lauffenburger DA: Making connections count. Nature 383: 390-391, 1996.
143. Stefansson S and Lawrence DA: The serpin PAI-e inhibits cell migration by blocking integrin alpha(v)beta(3) binding to vitronectin. Nature 383: 441-443, 1996.
144. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV and Chapman HA: Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555, 1996.
145. Griffiths CT, Parker LM and Fuller AF: Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 63: 235-240, 1979.
146. Bertelsen K: Tumor reduction surgery and long-term survival in advanced ovarian cancer: a Dacova study. Gynecol Oncol 38: 203-209, 1990.
147. Heintz APM, Hacker NF, Berek JS, Rose TP, Munoz AK and Lagasse LD: Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 67: 783-788, 1986.
148. Jänicke F, Hölscher M, Kuhn W, von Hugo R, Pache L, Siewert JR and Graeff H: Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70: 2129-2136, 1992.
149. Kuhn W, Jänicke F, Pache L, Hölscher M, Schattenmann G, Schmalfeldt B, Anderl H, Schüle G, Dettmar P, Siewert JR and Graeff H: Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III. Geburtshilfe Frauenheilkd 53: 293-302, 1993.
150. Benedetti PP, Greggi S, Scambia G, Salerno MG, Baiocchi G, Laurelli G, Menichella G, Pierelli L, Foddai ML and Serafini R: Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Eur J Cancer 31A: 1987-1992, 1995.
151. Van der Burg ME, van Lent LM, Buyse R, Kobierska A, Colombo N, Favalli G, Lacave AJ, Naredi M, Renard J and Pecorelli S: The effect of debulking surgery after combination chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332: 629-634, 1995.
152. Dumler I, Petri T and Schleuning WD: Interaction of urokinase-type plasminogen activator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett 322: 37-40, 1993.
153. Busso N, Masur SK, Lazega D, Waxman S and Ossowski L: Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 126: 259-270, 1994.
154. Dumler I, Petri T and Schleuning WD: Induction of c-fos in human ovarian cancer cells. FEBS Lett 343: 103-106, 1994.
155. Bohuslav J, Horejsi V, Hansmann C, Stöckl J, Weidle UH, Majdic O, Bartke I, Knapp W and Stockinger H: Urokinase plasminogen activator receptor, ß2-integrin, and src-kinases within a single receptor complex of human monocytes. J Exp Med 181: 1381-1390, 1995.
156. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F and Fazioli F: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15: 1572-1582, 1996.
157. Nguyen DHD, Hussaini IM and Gonias SL: Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem 273: 8502-8507, 1998.
158. Kirchheimer JC, Wojta J, Christ G and Binder BR: Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J 1: 125-128, 1987.
159. Kirchheimer JC, Christ G and Binder BR: Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme. Eur J Biochem 181: 103-107, 1989.
160. Kirchheimer JC, Wojta J, Christ G and Binder BR: Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci USA 86: 5424-5428, 1989.
161. Klagsbrun M and Baird A: A dual receptor system is required for basic fibroblast growth factor activity. Cell 67: 229-231, 1991.
162. Saksela O and Rifkin DB: Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 110: 767-775, 1990.
163. Lyons RM, Gentry LE, Purchio AF and Moses HL: Proteolytic activation of latent transforming growth factor-ß from fibroblast conditioned medium. J Cell Biol 106: 1659-1665, 1988.
164. Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F and Comoglio PM: Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 270: 603-611, 1995.
165. Rabbani SA, Mazar AP, Bernier SM, Haq M, Bolivar I, Henkin J and Goltzman D: Structural requirements for the growth factor activity of the amino-terminal domain of urokinase. J Biol Chem 267: 14151-14156, 1992.
166. Buko AM, Kentzer EJ, Petros A, Menon G, Zuiderweg ERP and Virender KS: Characterization of a posttranslational fucosylation in the growth factor domain of urinary plasminogen activator. Proc Natl Acad Sci USA 88: 3992-3996, 1991.
167. Luther T, Magdolen C, Albrecht S, Kasper M, Riemer C, Kessler H, Graeff H, Müller M and Schmitt M: Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Pathol 150: 1231-1244, 1997.
168. Wilhelm O, Weidle U, Höhl S, Rettenberger P, Schmitt M and Graeff H: Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 337: 131-134, 1994.
169. Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J and Goltzman D: An aminoterminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 173: 1058-1064, 1990.
170. Kanse SM, Benzakour O, Kanthou C, Kost C, Lijnen HR and Preissner KT: Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders. Arterioscler Thromb Vasc Biol 17: 2848-2854, 1997.
171. He CJ, Rebibou JM, Peraldi MN, Meulders Q and Rondeau E: Growth factor-like effect of urokinase type plasminogen activator in human renal cells. Biochem Biophys Res Commun 176: 1408-1416, 1991.
172. Luparello C and Del Rosso M: In vitro anti-proliferative and anti-invasive role of amino-terminal fragment of urokinase type plasminogen activator on 8701-BC breast cancer cells. Eur J Cancer 32A: 702-707, 1996.
173. Berdel WE, Wilhelm OG, Schmitt M, Maurer J, Reufi B, von Marschall Z, Oberberg D, Graeff H and Thiel E: Urokinase-type plasminogen activator (uPA), a protease with cytokine-like activity in human HL-60 leukemic cell line. Int J Oncol 3: 607-613, 1993.
174. Waltz DA, Sailor LZ and Chapman HA: Cytokines induce urokinase-dependent adhesion of human myeloid cells; a regulatory role for plasminogen activator inhibitors. J Clin Invest 91: 1541-1552, 1993.
175. Waltz DA and Chapman HA: Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 269: 14746-14750, 1994.
176. Hynes RO and Lander AD: Contact and adhesive specificities in the associations, migrations, and targeting of cells and axons. Cell 68: 303-322, 1992.
177. Knudsen BS, Hapel PC and Nachman RL: Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest 80: 1082-1089, 1987.
178. Deng G, Royle D, Seiffert D and Loskutoff DJ: The PAI-1/ vitronectin interaction: two cats in a bag? Thromb Haemost 74: 66-70, 1995.
179. Van Meijer M and Pannekoek H: Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 9: 263-276, 1995.
180. Seiffert D and Loskutoff DJ: Evidence that type-1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. J Biol Chem 266: 2824-2830, 1991.
181. Gudewicz PW and Gilboa N: Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem Biophys Res Comm 147: 1176-1181, 1987.
182. Fibbi G, Ziehe M, Morbidelli L, Magnelli L and Del Rosso M: Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp Cell Res 179: 385-395, 1988.
183. Terranova VP, Maslow D and Markus G: Directed migration of murine and human tumor cells to collagenases and other proteases. Cancer Res 49: 4835-4841, 1989.
184. Del Rosso M, Anichini E, Pedersen N, Blasi F, Fibbi G, Pucci M and Ruggiero M: Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells. Biochem Biophys Res Commun 190: 347-352, 1993.
185. Anichini E, Fibbi G, Pucci M, Caldini R, Chevanne M and Del Rosso M: Production of second messengers following chemotactic and mitogenic urokinase receptor interaction in human fibroblasts and mouse fibroblasts transfected with human urokinase receptor. Exp Cell Res 213: 438-448, 1994.
186. Gyetko MR, Todd RF, Wilkinson CC and Sitrin RG: The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 93: 1380-1387, 1994.
187. Gyetko MR, Sitrin RG, Fuller JA, Todd RF, Petty. H and Standiford TJ: Function of the urokinase receptor (CD87) in neutrophil chemotaxis. J Leukoc Biol 58: 533-538, 1995.
188. Franco P, Iaccarino C, Chiaradonna F, Brandazza A, Iavarone C, Mastronicola MR, Nolli ML and Stoppelli MP: Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility J Cell Biol 137: 779-791, 1997.
189. Fazioli F, Resnati M, Sidenius N, Higashimito Y, Appella E and Blasi F: A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 16: 7279-7286, 1997.
190. Wilhelm O, Schmitt M, Höhl S, Senekowitsch R and Graeff H: Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 13: 296-302, 1995.
191. Engelhard H, Narang C, Homer R and Duncan H: Urokinase antisense oligodeoxynucleotides as a novel therapeutic agent for malignant glioma: in vitro and in vivo studies of uptake, effects and toxicity. Biochem Biophys Res Commun 227: 400-405, 1996.
192. Reuning U, Wilhelm O, Nishiguchi T, Guerrini L, Blasi F, Graeff H and Schmitt M: Inhibition of NF-κB-Rel A expression by antisense-oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-I. Nucleic Acids Res 23: 3887-3893, 1995.
193. Kitajima I, Shinohara T, Bilakovics J, Brown DA, Xu X and Nerenberg M: Ablation of transplanted HTLV-1 tax-transformed tumors in mice by antisense inhibition of NF-κB. Science 258: 1792-1795, 1992.
194. Quattrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S and Del Rosso M: Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res 55: 90-95, 1995.
195. Kook YH, Adamski J, Zelent A and Ossowski L: The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 13: 3983-3991, 1994.
196. Mohaman S, Chintala SK, Go Y, Bhattacharya A, Venkaiah B, Boyd D, Gokaslan ZL, Sawaya R and Rao JS: In vitro inhibition of human cell line invasiveness by antisense uPA receptor. Oncogene 14: 1351-1359, 1997.
197. Xing RH and Rabbani SA: Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth, and metastasis. Int J Cancer 67: 423-429, 1996.
198. Lu H, Yeh P, Guitton JD, Mabilat C, Desanlis F, Maury I, Legrand Y, Soria J and Soria C: Blockage of the urokinase receptor on cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin. FEBS Lett 356: 56-59, 1994.
199. Kobayashi H, Gotoh J, Hiroshima Y, Fujie M, Sugino D and Terao T: Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem 270: 8361-8366, 1995.
200. Ossowski L and Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611-619, 1983.
201. Appella E, Robinson EA, Ullrich SJ, Stoppelli M, Corti A, Casani G and Blasi F: The receptor binding sequence of urokinase. J Biol Chem 262: 4437-4440, 1987.
202. Bürgle M, Koppitz M, Riemer C, Kessler H, König B, Weidle UH, Kellermann J, Lottspeich F, Graeff H, Schmitt M, Goretzki L, Reuning U, Wilhelm O and Magdolen V: Inhibition of the interaction of urokinase (uPA) with its receptor (uPAR, CD87) by synthetic peptides. Biol Chem 378: 231-237, 1997.
203. Kobayashi H, Ohi H, Shinohara H, Sugimura M, Fujii T, Terao T, Schmitt M, Goretzki L, Chucholowski N, Jänicke F and Graeff H: Saturation of tumor cell surface receptors for the urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion. Br J Cancer 67: 537-544, 1993.
204. Rabbani SA, Harakidas P, Davidson DJ, Henkin J and Mazar AP: Prevention of prostate cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 63: 840-845, 1995.
205. Alonso DF, Farias EF, Ladeda V, Davel L, Puricelli L and Joffe EBD: Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res Treat 40: 209-223, 1996.
206. Jankun J, Keck RW, Skrzypczak-Jankun J and Swiercz R: Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res 57: 559-563, 1997.
207. Towle MJ, Lee A, Maduakor EC, Schwartz CE, Bridges AJ and Littlefield BA: Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamines: an important new class of selective synthetic urokinase inhibitors. Cancer Res 53: 2553-2559, 1993.